A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects
Recently identified interleukin-28 and -29 belong to a novel type III interferon (IFN) family, which could have distinct biological properties from type I and II IFNs. Type I IFNs, IFN-α/β, have been clinically applied for treating a certain kind of malignancies for over 30 years, but a wide range o...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2011/479013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850230304404406272 |
|---|---|
| author | Masatoshi Tagawa Kiyoko Kawamura Quanhai Li Yuji Tada Kenzo Hiroshima Hideaki Shimada |
| author_facet | Masatoshi Tagawa Kiyoko Kawamura Quanhai Li Yuji Tada Kenzo Hiroshima Hideaki Shimada |
| author_sort | Masatoshi Tagawa |
| collection | DOAJ |
| description | Recently identified interleukin-28 and -29 belong to a novel type III interferon (IFN) family, which could have distinct biological properties from type I and II IFNs. Type I IFNs, IFN-α/β, have been clinically applied for treating a certain kind of malignancies for over 30 years, but a wide range of the adverse effects hampered the further clinical applications. Type III IFNs, IFN-λs, have similar signaling pathways as IFN-α/β and inhibits proliferation of tumor cells through cell cycle arrest or apoptosis. Restricted patterns of type III IFN receptor expression in contrast to ubiquitously expressed IFN-α/β receptors suggest that type III IFNs have limited cytotoxicity to normal cells and can be a possible anticancer agent. In this paper, we summarize the current knowledge on the IFN-λs-mediated tumor cell death and discuss the functional difference between type I and III IFNs. |
| format | Article |
| id | doaj-art-213f62c83ec6410bb242aaa0fc47c5bc |
| institution | OA Journals |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-213f62c83ec6410bb242aaa0fc47c5bc2025-08-20T02:03:55ZengWileyClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/479013479013A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor EffectsMasatoshi Tagawa0Kiyoko Kawamura1Quanhai Li2Yuji Tada3Kenzo Hiroshima4Hideaki Shimada5Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, JapanDivision of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, JapanDivision of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, JapanDepartment of Respirology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, JapanDepartment of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, 477-96 Owada-Shinden, Yachiyo 276-8524, JapanDepartment of Surgery, School of Medicine, Toho University, Tokyo 143-8540, JapanRecently identified interleukin-28 and -29 belong to a novel type III interferon (IFN) family, which could have distinct biological properties from type I and II IFNs. Type I IFNs, IFN-α/β, have been clinically applied for treating a certain kind of malignancies for over 30 years, but a wide range of the adverse effects hampered the further clinical applications. Type III IFNs, IFN-λs, have similar signaling pathways as IFN-α/β and inhibits proliferation of tumor cells through cell cycle arrest or apoptosis. Restricted patterns of type III IFN receptor expression in contrast to ubiquitously expressed IFN-α/β receptors suggest that type III IFNs have limited cytotoxicity to normal cells and can be a possible anticancer agent. In this paper, we summarize the current knowledge on the IFN-λs-mediated tumor cell death and discuss the functional difference between type I and III IFNs.http://dx.doi.org/10.1155/2011/479013 |
| spellingShingle | Masatoshi Tagawa Kiyoko Kawamura Quanhai Li Yuji Tada Kenzo Hiroshima Hideaki Shimada A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects Clinical and Developmental Immunology |
| title | A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects |
| title_full | A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects |
| title_fullStr | A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects |
| title_full_unstemmed | A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects |
| title_short | A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects |
| title_sort | possible anticancer agent type iii interferon activates cell death pathways and produces antitumor effects |
| url | http://dx.doi.org/10.1155/2011/479013 |
| work_keys_str_mv | AT masatoshitagawa apossibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT kiyokokawamura apossibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT quanhaili apossibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT yujitada apossibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT kenzohiroshima apossibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT hideakishimada apossibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT masatoshitagawa possibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT kiyokokawamura possibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT quanhaili possibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT yujitada possibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT kenzohiroshima possibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects AT hideakishimada possibleanticanceragenttypeiiiinterferonactivatescelldeathpathwaysandproducesantitumoreffects |